NKTR Drug delivery Company Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NKTR Drug delivery Company

NKTR 55.97

+1.5%

Nov 7 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who wrote (440)	11/6/2018 9:50:57 AM
From: Miljenko Zuanic	Read Replies (1) of 507

Thanks. IF you eliminate super-progressed (one or two from first 28, and 2 from next 10....ASCO), than response rate is 5/8 or +60%, which is better than O + Y. Even IF they do have 50% RR in P3-M study, with durable response, toxicity of the regime will be much better than O + Y. Nonetheless, I do believe that they did not fully optimized doses (0.09mg/kg) should not be that TOXIC???? I am not happy with my bet on NKTR! :-(

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next